Evidence map›Paper›PMID 24268630›Full record

ArticleOral oncology2014

Silencing Met receptor tyrosine kinase signaling decreased oral tumor growth and increased survival of nude mice.

X Tao, K S Hill, I Gaziova, S K Sastry, S Qui, P Szaniszlo, S Fennewald, V A Resto, L A Elferink

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oral oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016
    Review
  9. Article
  10. Thymoquinone inhibits proliferation and invasion of human nonsmall-cell lung cancer cells via ERK pathway.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

X TaoDepartment of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555-1074, United States.
K S HillDepartment of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555-1074, United States.
I GaziovaDepartment of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555-1074, United States.
S K SastryDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555-1074, United States; Department of Sealy Center for Cancer Biology, University of Texas Medical Branch, Galveston, TX 77555-1074, United States.
S QuiDepartment of Pathology, University of Texas Medical Branch, Galveston, TX 77555-1074, United States; Department of Sealy Center for Cancer Biology, University of Texas Medical Branch, Galveston, TX 77555-1074, United States.
P SzaniszloDepartment of Otolaryngology, University of Texas Medical Branch, Galveston, TX 77555-1074, United States.
S FennewaldDepartment of Otolaryngology, University of Texas Medical Branch, Galveston, TX 77555-1074, United States.
V A RestoDepartment of Otolaryngology, University of Texas Medical Branch, Galveston, TX 77555-1074, United States; Department of Sealy Center for Cancer Biology, University of Texas Medical Branch, Galveston, TX 77555-1074, United States.
L A ElferinkDepartment of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX 77555-1074, United States; Department of Sealy Center for Cancer Biology, University of Texas Medical Branch, Galveston, TX 77555-1074, United States. Electronic address: lisa.elferink@utmb.edu.
The University of Texas Medical Branch at Galveston · US

Funding

Regulation and Function of PTP-PEST in colon carcinomaR01CA118405 · NCI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI SASTRY, SARITA KANDULA · 2007 to 2012
$1.7M
Cellular Response to cMet EndocytosisR01CA119075 · NCI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI ELFERINK, LISA A. · 2006 to 2011
$1.3M
Physiologic Study of Lymphatic MetastasisK08CA132988 · NCI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI RESTO, VICENTE ANDRES · 2009 to 2013
$795k
NCI NIH HHS CA118405NCI NIH HHS CA119075NCI NIH HHS CA-132988NCI NIH HHS K08 CA132988NCI NIH HHS R01 CA118405NCI NIH HHS R01 CA119075
6 · The paper itself

Abstract

objectivesThe hepatocyte growth factor receptor (Met) is frequently overexpressed in Head and Neck Squamous Cell Carcinoma (HNSCC), correlating positively with high-grade tumors and shortened patient survival. As such, Met may represent an important therapeutic target. The purpose of this study was to explore the role of Met signaling for HNSCC growth and locoregional dissemination. MATERIALS AND

methodsUsing a lentiviral system for RNA interference, we knocked down Met in established HNSCC cell lines that express high levels of the endogenous receptor. The effect of Met silencing on in vitro proliferation, cell survival and migration was examined using western analysis, immunohistochemistry and live cell imaging. In vivo tumor growth, dissemination and mouse survival was assessed using an orthotopic tongue mouse model for HNSCC.

resultsWe show that Met knockdown (1) impaired activation of downstream MAPK signaling; (2) reduced cell viability and anchorage independent growth; (3) abrogated HGF-induced cell motility on laminin; (4) reduced in vivo tumor growth by increased cell apoptosis; (5) caused reduced incidence of tumor dissemination to regional lymph nodes and (6) increased the survival of nude mice with orthotopic xenografts.

conclusionMet signaling is important for HNSCC growth and locoregional dissemination in vivo and that targeting Met may be an important strategy for therapy.

Indexed as

AnimalsApoptosisCell MovementCell ProliferationIndolesLymphatic MetastasisMiceMice, NudeNeoplasms, ExperimentalPiperazinesProto-Oncogene Proteins c-metRNA, Small InterferingSignal TransductionSulfonamidesTongue Neoplasms((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide)IndolesMET protein, humanPiperazinesProto-Oncogene Proteins c-metRNA, Small InterferingSulfonamidesHead and neck squamous cell carcinomaHGF receptorMETOral cancerTumorigenesis

Identifiers

PMID24268630
PMCPMC4097605
OpenAlexW2033422297

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.